



## MIXED HYDROTROPIC SOLUBILISATION- A NOVEL TECHNIQUE TO ENHANCE THE DISSOLUTION OF FEBUXOSTAT

Megha Verma<sup>1\*</sup>, Kaminee Sahu<sup>1</sup>, Ankita Singh Alice<sup>2</sup>, Anupam Jaiswal<sup>1</sup>,  
Abhilasha Singh<sup>3</sup> Stuti Pandey<sup>1</sup>

<sup>1</sup>Gyan Ganga Institute of Technology & Sciences, Pharmacy Tilwara Ghat,  
Jabalpur- 482003, Madhya Pradesh, India

<sup>2</sup>Kalaniketan Polytechnic College, Jabalpur 482003, Madhya Pradesh, India

<sup>3</sup>Mittal Institute of Pharmacy, Bhopal 462001 Madhya Pradesh, India

\*Corresponding email- meghapharma@rediffmail.com

---

### ABSTRACT

The aim of this study was to improve the dissolution of water insoluble drug by mixed hydrotropic solid dispersion technology. The poor dissolution characteristic of water insoluble drugs is a major challenge for pharmaceutical professionals. Mixed hydrotropic solid dispersion (HSD) technology contains the blends of hydrotropic agents, gives synergistic effect on solubility of poorly aqueous soluble drug. This technique restricts the use of large amount of individual hydrotropic agent, thus minimizes the toxic effects of individual hydrotropic agent arising due to their high concentration. HSDs were prepared by using hydrotropic blend of 15% sodium benzoate, 10% Niacinamide and 5% sodium citrate by solvent evaporation method. Hydrotropic agents previously evaluated for their compatibility with drug by FT-IR study. Prepared solid dispersions were evaluated by XRD and dissolution studies, compared with the pure febuxostat powder and physical mixture of drug and hydrotropic agent. The result showed no interaction between the drug and hydrotropic polymer and significant increase in the dissolution rate.

**Keywords:** Febuxostat, Solvent evaporation, Mixed hydrotropic solid dispersion, Dissolution, Sodium benzoate, Sodium citrate, Niacinamide

---

### INTRODUCTION

Most of the chemical entities that are being discovered are lipophilic and have poor aqueous solubility. Because of their low aqueous solubility and high permeability, dissolution from oral delivery systems forms the rate limiting step in their absorption and systemic bioavailability. A more than 60% drug product suffers from poor water solubility. Currently number of techniques addressed the poor solubility and dissolution rate of poorly soluble drugs. Hydrotropic solubilization is one of them. Hydrotropy is a

solubilization phenomenon whereby addition of large amount of second solute results in an increase in the aqueous solubility of another solute. Concentrated aqueous hydrotropic solutions of sodium benzoate, sodium salicylate, urea, nicotinamide/niacinamide, sodium citrate and sodium acetate have been observed to enhance the aqueous solubility of many poorly water-soluble drugs. Aqueous injection of caffeine with sodium benzoate (a hydrotropic agent) is a classic example (12). A Hydrotropes is a compound that solubilizes hydrophobic compound in aqueous solutions. Typically Hydrotropes consist of a hydrophilic part and a hydrophobic part (like surfactants) but the hydrophobic part is generally too small to cause spontaneous self- aggregation. Hydrotropes do not have a critical concentration above which self- aggregation suddenly starts to occur (as found for micelle forming surfactant have a critical micelle concentration). Hydrotrophy is used as solubility enhancement for different class of drugs such as anti-tumor, anti-viral, anti-pyretic, analgesic drugs, xanthine derivatives. (13)

## MATERIALS AND METHODS

### Material

Febuxostat is a kind gift sample from Ipca laboratories, Ratlam, Madhya Pradesh. All the reagents and solvents were of analytical grade.

### Selection of hydrotropic blends

As evident from the research work,() it was found that there were significant enhancement in aqueous solubility (a synergistic effect) of poorly water soluble drug by use of a combined hydrotropic blend. Keeping this point in mind and using the total dissolved concentration at least 30% w/v (at random) different blends of hydrotropic agents (sodium benzoate, niacinamide and sodium citrate) (table- 1) were made and the solubility of febuxostat was determined with them.

**Table1. Composition of hydrotropic blends selected for febuxostat**

S. No.	Combination	Total con. (% w/v)	Ratio
1.	B+ N + C	30%	15+ 10 + 5
2.	N+ B + C	30%	15+ 10 + 5
3.	B+ N + C	30%	10+ 10 +10
4.	B+ N + C	30%	5+ 10 + 15
5.	B+ N + C	30%	10+ 5 +15

**B= SODIUM BENZOATE; N= NICOTINAMIDE; C= SODIUM CITRATE**

### Determination of equilibrium solubility studies in different blends of hydrotropic agents

3 ml of particular blend of hydrotropic agent was taken in a 10 ml volumetric flask and excess amount of drug was added and shaken mechanically by mechanical shaker until

saturated solution was formed. The solution was centrifuged at 2000 rpm for 10 min in Ultra- centrifuge and resulting solution was filtered through whatman filter paper grade 41. Aliquot was suitably diluted with distilled water and analysed by using uv-spectrophotometer at 315 nm.

S. No.	Hydrotropic agent	Solubility in 30% hydrotropic agent	Solubility enhancement ratio
1.	Nicotinamide	0.559	34.33
2.	Sodium benzoate	0.793	48.71
3.	Sodium citrate	0.097	6.06

**Table 2 - Solubility studies in different blends of hydrotropic agents**

Highest solubility was observed in 30% sodium benzoate. Then in order to decrease the concentration of sodium benzoate, different combination of hydrotropic agent in different ratios were made to determine enhancement in solubility.

**Table 3- Different combination of hydrotropic agent in different ratios to determine enhancement in solubility**

S. No.	Combination	Ratio	Solubility % w/v
1.	B+ N + C	15+ 10 + 5	4.3
2.	N+ B + C	15+ 10 + 5	3.9
3.	B+ N + C	10+ 10 +10	3.3
4.	B+ N + C	5+ 10 + 15	2.8
5.	B+ N + C	10+ 5 +15	3.0

### **Formulation of Hydrotropic Solid Dispersion of Febuxostat by Solvent Evaporation Method**

For the preparation of hydrotropic solid dispersion containing Febuxostat and hydrotropic blend in different ratio composition described in table were weighed accurately. Minimum quantity of distilled water at 80- 85 °C contained in a 100 ml beaker was used to dissolve the B+N+C for quick dissolution. Then Febuxostat was added to this beaker at (30-40 °C) and a Teflon coated magnetic bead was dropped in it, so as to facilitate the evaporation of water. As evaporation proceeded speed of magnetic bead decreased and it stopped stirring when most of the water was evaporated and indicating the formation of wet solid dispersion.

**Table 4- Composition of hydrotropic solid dispersion**

S. No.	Drug hydrotropic blend	Febuxostat	Benzoate	Niacinamide	Citrate
1.	1 : 6	1 gm	3 gm	2 gm	1 gm
2.	1 : 8	1 gm	4 gm	2.67 gm	1.34 gm
3.	1 : 10	1 gm	5 gm	3.34 gm	1.67 gm

Semisolid mass so formed spread on several watch glasses in thin layers for quick drying. The watch glasses were kept in oven, at 40 °C for drying. After drying, it was triturated with the help of pestle mortar and again kept in oven for drying. After complete drying, the powder of solid dispersion was passed through sieve no. 40 and finally store in air tight glass bottle.

#### **Physical Mixture of Febuxostat-**

Drug carrier ratio 1:6, 1:8 and 1:10 were used for preparation of physical mixture. Accurate amount of ingredients were weighed and mixed intensely for 10 minutes using glass pestle and mortar with intensive trituration. Then, powder mass was shifted through sieve number 40. After this, the physical mixture was stored in air- tight glass bottle.

#### **Determination of Drug Content in Febuxostat Formulation (HSD And PM)-**

Powdered solid dispersion/ PM containing about 10 mg of febuxostat was accurately weighed and transferred to a 100 ml volumetric flask. About 50 ml of distilled water was added and flask was shaken to dissolve the formulation completely. Then volume was made up to the mark with distilled water and the absorbance of this solution was measured at 315 nm against reagent blank. In each case, analysis was carried out in triplet. The drug content was determined using regression equation-

$$Y = 0.0648 X + 0.0029$$

**Table 5- Drug contents of physical mixture and hydrotropic solid dispersion**

S. No.	Drug : Hydrotropic blend	Percentage drug ( mean $\pm$ SD)	
	BLEND	PHYSICAL MIXTURE	HYDROTROPIC SD
1.	1 : 6	65 $\pm$ 1.417	112.4 $\pm$ 2.557
2.	1 : 8	90.433 $\pm$ 1.222	135.733 $\pm$ 2.260
3.	1 : 10	97.333 $\pm$ 2.371	106.9 $\pm$ 1.652

#### **POWDER X- RAY DIFFRACTION-**

X- ray diffraction analysis for pure drug and hydrotropic solid dispersion of febuxostat were done by X- ray diffractometer( Figure.1-3)

### Dissolution Rate Studies of Drug and their Formulations-

Solid dispersion and physical mixture of febuxostat were tested in dissolution rate studies using USP XXIV (type II) dissolution test apparatus (model TDT4P, Electrolab Mumbai, INDIA) with paddle to rotate at 50 rpm. 900ml of distilled water was taken as dissolution media with temperature of  $37 \pm 0.5^\circ\text{C}$ . At definite time interval 1ml of sample were withdrawn and were analysed for drug content. Withdrawn sample were also replaced with fresh dissolution media. Calculations for the amount of drug were done using respective regression equation and the results of the dissolution studies. (table- 6)

### Chemical Stability Studies-

Powders of various formulation were kept in 10 ml amber coloured glass bottle which plugged and sealed. The febuxostat content of the febuxostat hydrotropic solid dispersion preparations was analyzed at 0, 1, 2, 4, and 6 months to compare the degradation over time. Bottles were kept at room temperature. The drug contents were determined by UV analysis. The initial drug content for each formulation was considered as 100%.

### RESULT AND DISCUSSION

Solubility enhancement ratio of febuxostat in different hydrotropic blend like niacinamide, sodium benzoate and sodium citrate was found to be 34.33, 48.71, 6.06. The highest solubility enhancement was found in sodium benzoate. (Table 2) Percentage solubility of different hydrotropes was determined and maximum solubility was observed in blend containing sodium benzoate, niacinamide and sodium citrate in ratio 15: 10 : 5. Therefore this combination was used for the preparation of solid dispersion.

Solid dispersion of various hydrotropes with the drug was prepared in various ratio using solvent evaporation technique (Table 4). The prepared solid dispersion were further characterized by XRD and drug content. XRD analysis was performed. In the XRD of pure drug sharp peak was observed at  $10-20^\circ$  indicating the presence of crystalline drug while solid dispersion show sharp peak at  $10-20^\circ$ . The data reveals that typical drug crystalline peak was still detectable in the solid dispersion, thus confirms the presence of the little amount of crystalline drug in solid dispersion. However sharp peak corresponding to the drug were absent in the XRD of solid dispersion. This suggesting the crystalline nature of drug has decreased in the solid dispersion. Decrease in crystallinity of drug and hydrotrope may contribute to enhancement of dissolution of drug.

*In-vitro* dissolution rate study were performed at  $37 \pm 0.5^\circ\text{C}$  (Table 6), it showed that the bulk drug sample exhibited poor drug release profile. Initial rates of dissolution of drug from HSDs were very quick as compared with initial rates of dissolution from bulk drug sample. Drug release profile from HSDs was better than the drug release profile from PM. Also, it is indicated that as the proportions of water soluble carrier was increased in solid dispersions, there was negligible difference in dissolution behavior. As the initial rates of dissolution of drug from HSDs were significantly high as compared with initial

dissolution rates from bulk drug sample, the quick onset of action and better extent of absorption is expected after oral administration of these HSD.

## CONCLUSION-

In the field of pharmaceutical industries the major problem associated various drug is their poor water solubility especially for oral administration. Aqueous solubility of drug for oral preparation is very important step for better bioavailability of drug in systemic circulation. There are several approaches are used to enhanced the drug solubility of poor water soluble drugs like co- solvency, complexation and pH alteration, by chemical modification of drug and by hydrotropic solubilization etc. Among these approaches hydrotropy is suitable choice of scientist to designate the increase in aqueous solubility of various poorly water-soluble compounds (febuxostat etc.) due to the presence of a large amount of additives. Concentrated aqueous solutions of sodium benzoate, sodium salicylate, urea, nicotinamide, sodium citrate, sodium acetate and sodium ascorbate have been employed to enhance the aqueous solubilities of a large number of poorly water soluble drugs. Problem associated with oral formulation of febuxostat is slow solubilisation rate of febuxostat, less aqueous solubility, high cost of organic solvent, high cost of formulation, narrow therapeutic range, fluctuation in plasma concentration and serious side effects with convectional dosage form. Hydrotropic solubilization is a technique to improve the dissolution of poor water soluble drug. In this technique addition of hydrotropic agents result in the improve aqueous solubility of poor soluble drug. Various hydrotropic agents are used to enhance aqueous solubility of drug like sodium benzoate, sodium citrate, sodium acetate, niacinamide, urea etc. Aqueous injection of caffeine with sodium benzoate is a better example of hydrotropy.

**Table 6- Dissolution profile of pure drug, PM and HSD in distilled water**

Time (min)	Cumulative percentage of drug dissolved (mean $\pm$ SD)				
	Pure drug	1 : 10 PM	1: 6 HSD	1 : 8 HSD	1: 10 HSD
3	12.9 $\pm$ 0.264	38.30 $\pm$ 0.40	73.23 $\pm$ 0.981	88.13 $\pm$ 0.680	79.93 $\pm$ 0.057
6	14.04 $\pm$ 0.850	45.73 $\pm$ 0.404	92.86 $\pm$ 1.357	94.30 $\pm$ 0.173	93.56 $\pm$ 1.761
10	20.26 $\pm$ 0.321	51.33 $\pm$ 0.602	96.23 $\pm$ 0.960	96.66 $\pm$ 0.208	96.36 $\pm$ 0.709
15	27.86 $\pm$ 0.56	58.70 $\pm$ 0.360	98.73 $\pm$ 0.288	99.10 $\pm$ 0.655	98.46 $\pm$ 0.550
30	37.50 $\pm$ 1.3	69.40 $\pm$ 0.529	98.96 $\pm$ 0.0507	99.83 $\pm$ 0.057	99.73 $\pm$ 0.152




Fig 1- 1:6 HSD




Fig 2- 1:8 HSD




Fig 3- 1:8 PM

## REFERENCES

1. Li EK. *Et al.*, gout: a review of its a etiology and treatment, Hong k ong med. J. 2004; 10: 261-70.
2. Tripathi KD, essentials of medical pharmacology, jaypee brothers medical publishers (p) Vol.7, 2013, 210-217.
3. Choi HK, Mount DB, Reginato AM, Pathogenesis of gout, Ann Intern Med 2005; 143:499.
4. Becker MA, Jolly M, Clinical gout and the pathogenesis of hyperuricemia, 2005: 2303-39.

5. Parle Milind *et al*, understanding gout beyond doubt, international research journal of pharmacy, vol. 4 (9), 2013. ]
6. Hyon k. choi *et al*, pathogenesis of gout- a review article. American college of physician internal medicine. 2005; 143: 499- 516.
7. Fernando Perez- Ruiz, treating to target: a strategy to cure gout, oxford university press on behalf of the british society for rheumatology 2009, 48 ii9- ii14.
8. Terkeltaub Robert, update on gout: new therapeutic strategies and options, rheumatology section, veterans affairs medical center, university of California, vol. 6, 2010.
9. Pandey anjana *et al*, febuxostat- a new treatment for hyperuricaemia in gout- a review article. National J. of physiology pharmacy and pharmacology. 2012; 2(1): 23-28.
10. Singh Jasvinder A. *et al*, Risk Factors for Gout and Prevention: A Systematic Review of the Literature, The National Center for Biotechnology Information advances science and health, vol. march 23 (2), 2011, 192-202.
11. Lindsey A. MacFarlane and Seoyoung C. Kim, Gout: a review of non-modifiable and modifiable risk factors, The National Center for Biotechnology Information advances science and health, vol. November 40 (4), 2014, 581-604.
12. Al- allaf wahab- abdul *et al*, gout- evidence based update with new therapeutic strategies, new cross hospital and university of Birmingham, sudan med. J. 2012 december; 48 (3).
13. [www.nhs.uk/conditions/gout/pages/treatment.aspx](http://www.nhs.uk/conditions/gout/pages/treatment.aspx)  
59
14. Gaffo AL, Saag KG. Management of hyperuricemia and gout in CKD. Am J Kidney Dis. 2008; 52(5):994-1009.
15. Del Favero A. Anti-inflammatory and antipyretic analgesics and drugs used in gout. In: Aronson JK, editor. Side Eff Drugs. Elsevier; 2008. p. 125-136
16. Sharma Desh Raj, Jain Amit K, Talsera Amit, solubilization of poorly soluble drugs: A review, international journal of pharmaceutical studies and research, vol. 2, issue 1, jan-march 2011, 91-99
17. Brahmankar DM, Jaiswal SB, Biopharmaceutics and pharmacokinetics a treatise, 1 edition, 1995, 100-500
18. Lokhandwala hussain, deshpane ashwini and deshpane shirish, kinetic modelling and dissolution profiles comparison: an overview, international journal of pharma and bioscience, January 2013, 4 (1), 728-737
19. Boris shekunov and Eda ross Montgomery, theoretical analysis of drug dissolution : I. solubility and intrinsic dissolution rate, journal of pharmaceutical sciences, 105 (2016), 2685- 2697
20. The United States Pharmacopeia, USP 30-NF 25, 2007.



21. British Pharmacopoeia, 2009.

22. Savjani ketan, gajjar anuradha and savjani jignasa, drug solubility: importance and enhancement techniques, international scholarly research notices, vol. 2012, article id 195727, 10

23. www.usfda.gov

24. Jadhav P. B., Pandey P. S., phase solubility analysis- a technique of purity determination, world research journal of pharmaceutical research, vol. 1, issue 1, 2013, 05-11

25. Linda A. Felton, Remington- essential of pharmaceuticals, pharmaceutical press, 2013, 219-237

26. Nwodo NJ, Nnadi CO *et al.*, development and validation of novel hydrotropic solubilization method for spectrophotometric determination of halofantrin in pure and solid dosage form, scholars academic journal of pharmacy, 2013; 2(4): 298-303  
60

27. Kumar sampath V. *et al.*, A review on solubility enhancement using hydrotropic phenomena, international journal of pharmacy and pharmaceutical science, vol. 6, issue 6, 2014

28. Pandit A, Sharma M.M. Intensification of heterogeneous reactions through hydrotropy. Alkaline hydrolysis of esters and oximation of cyclododecanone. Chem. Eng. Sci.1987; 42: 2519-2523.

29. Chen X, Micheu J.C. Hydrotrope Induced auto catalysis in the biphasic alkaline hydrolysis of aromatic esters. J.Colloid Interface Sci. 2002; 249: 172-179. 1

30. Akhilesh Kumar Jain. Solubilization of indomethacin using hydrotropes for aqueous injection. European Journal of Pharmaceutics and iopharmaceutics. 2008; 68: 701-714.

31. Maheshwari R.K, Chaturvedi S.C, Jain N.K. Novel application of hydrotropic Solubilization in the quantitative analysis of some NSAIDs and their solid dosage forms. Indian J. Pharm. Sci. 2007; 69: 101-105.

32. Dandekar D.V, Gaikar V.G. Hydrotropic extraction of curcuminoids from turmeric. Sep. Sci. Technol.2003; 38(5): 1185-1215.

33. Colonia E.J, Dixit A.B, Tavaré N.S. Separation of o- and pchlorobenzoic acids: hydrotropy and precipitation. J.Crys. Growth.1996; 166: 976-980.

34. Coffman R.E, Kildsig D.O. Hydrotropic solubilization-- mechanistic studies. Pharmaceutical Research.1996; 13(10): 1460-1463.

35. Dharmesh Varade, Pratap Bahadur. Effect of hydrotropes on the aqueous solution behavior of surfactants. Journal of Surfactants and Detergents.2004; 7(3): 257-261.

36. Dharmendra Kumar M, Nagendra Gandhi, N. Effect of hydrotropes on solubility and mass transfer coefficient of amyl acetate. Bio process. Eng.2000; 23: 31-36.

37. Dharmendra Kumar M, Nagendra Gandhi N. Effect of hydrotropes on solubility and mass transfer coefficient of methyl salicylate. J.Chem. Eng. 2000; 45: 419-423.

38. Deno N.C, Spink C.H. The Mc-Devit long equation for salt effects on non-electrolytes. J.Phys. Chem.1963; 67: 1347-1349.

39. Friberg S.E. Hydrotropes. Surface Science.1997; 2: 490-494.

61

40. Gaspar Gonzalez, Eduardo J, Nassar, Maria Elizabete D, Zanicuelli. Examination of the Hydrotropic Effect of Sodium pToluenesulfonate on a Nonionic Surfactant (C12E6) Solution. Journal of Colloid and Interface Science.2000; 230(2): 223-228.

41. Iqar Ahmad Khan, Ahmad Jahan Khanam, Mohmad Shafi Sheikh, Kabir-ud-Din. Influence of ionic and nonionic hydrotropes on micellar behavior of a cationic gemini surfactant butanediyl-1, 4-bis (dimethyl cetyl ammonium bromide). Journal of Colloid and Interface Science. 2011; 359(2): 467-473.

42. Jadhav V.K, Dixit B.A, Tavare N.S. Solubilities of m- and p-aminoacetophenones in hydrotrope solutions. J. Chem. Eng. Data. 1995; 40: 669-673.

43. Paul O, Raynaud-Lacroze, Narayan S, Tavare. Separation of 2- Naphthol: Hydrotropy and Precipitation. Ind. Eng. Chem. Res.1993; 32: 685-691.

44. Gibson. Pharmaceutical preformulation and formulation. 2nd ed. Interpharm Press. 2001: 28-29.

45. Martin A. Micromeritics in physical pharmacy. 2nd ed. Philadelphia PA.1988:273.

36. Goel A, Sharma M, Sharma S, Haffez A, Arora J. Pharmacokinetic data and solubility profile of antihypertensive drugs. Int J Pharma Prof Res. 2010;1: 61-77.

46. Kapadiya nidhi, Singhvi indrajeet *et al.*, hydrotropy: a promising tool for solubility enhancement : a review, international journal of drug development and research, 2011, 3(2): 26-33

47. K. Szabo, P. Wang, B. Peles-Lemli, Y. Fang, L. Kollar, and S. Kunsagi-Mate, Structure of aggregate of hydrotropic p-toluene sulfonate and hydroxy aceto phenone isomers, Colloids and Surfaces A: Physicochem. Eng. Aspects, 422 (2013), pp. 143–147

48. E. Friberg, C. Brancewicz, O/W microemulsions and hydrotropes: the coupling action of a hydrotrope, Langmuir, 10 (1994), pp. 2945–2949

49. M. Hatzopoulos, J. Eastoe, J. Peter, S. Rogers, R. Heenan, R. Dyer, Are hydrotropes distinct from surfactants, Langmuir, 27 (2011), pp. 12346–1235

50. A. Saleh, L. El-Khordagui, Hydrotropic agents: a new definition, Int. J. Pharm., 24 (1985), pp. 231–238

51. J. Kim, S. Kim, M. Papp, K. Park, R. Pinal, Hydrotropic solubilization of poorly water-soluble drugs, J. Pharm. Sci., 99 (2010), pp. 3953–3965

52. K. Lai, Liquid Detergents, (second ed.)CRC Press, Boca Raton, FL (2006)

62

53. G. Verma, V. Aswal, G. Fritz-Popovski, C. Shah, M. Kumar, P. Hassan, Dilution induced thickening in hydrotrope-rich rod-like micelles, J. Colloid. Interface. Sci., 359 (2011), pp. 163–170

54. W. de Paula, A. Denadai, M. Santoro, A. Braga, R. Santos, R. Sinisterra, Supramolecular interactions between losartan and hydroxypropyl- $\beta$ -CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies, *Int. J. Pharm.*, 404 (2011), pp. 116–123
55. R. Da Silva, M. Spitzer, L. Da Silva, *et al.*, Investigations on the mechanism of aqueous solubility increase caused by some hydrotropes, *Thermochimica. Acta*, 328 (1999), pp. 161–167
56. V. Gaikar, P. Pathak, Selective solubilization of isomers in hydrotrope solution o-p-chlorobenzoic acids and o-p-nitro anilines, *Sep. Sci. Technol.*, 34 (1999), pp. 439–459
57. S. Shimizu, N. Matubayasi, Hydrotropy: monomer-micelle equilibrium and minimum hydrotrope concentration, *J. Phys. Chem. B.*, 118 (2014), pp. 10515–10524
58. A. Badwan, L. El-Khordagui, A. Saleh, S. Khalil, The solubility of benzodiazepines in sodium salicylate solution and a proposed mechanism for hydrotropic solubilization, *Int. J. Pharm.*, 13 (1983), pp. 67–74
59. G. Ferreira, D. Perigo, M. Politi, S. Schreier, Effect of anions from the Hofmeister series and urea on the binding of the charged and uncharged forms of the local anesthetic tetracaine to zwitter ionic micelles, *Photochem. Photobiology*, 63 (1996), pp. 755–761
60. R. Coffman, D. Kildsig, Effect of nicotinamide and urea on the solubility of riboflavin in various solvents, *J. Pharm. Sci.*, 85 (1996), pp. 951–954
61. A. Khanam, M. Sheikh, I. Khan, Kabir-ud-Din, Aggregational behavior of alkanediyl- $\alpha$ - $\omega$ -bis (tetradecyl dimethyl ammonium) dibromide series with ionic and non-ionic hydrotropes at different temperatures, *J. Ind. Eng. Chem.*, 20 (2014), pp. 3453–3460
62. M. Rub, N. Azum, D. Kumar, F. Khan, A. Asiri, Clouding phenomenon of amphiphilic drug promazine hydrochloride solutions: Influence of pharmaceutical excipients, *J. Ind. Eng. Chem.*, 21 (2015), pp. 1119–1126
63. S. Lee, K. Huh, J. Lee, Y. Cho, R. Galinsky, K. Park, Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization, *Biomacromolecules*, 8 (2007), pp. 202–208
- 63
64. A. Malik, M. Abdullah, A. Naved, Kabir-ud-Din, Investigation of micellar and phase separation phenomenon of phenothiazine drug promazine hydrochloride with anionic hydrotropes, *J. Ind. Eng. Chem.*, 20 (2014), pp. 2023–2034
65. S. Schreier, S. Malheiros, E. de Paula, Surface active drugs: self-association and interaction with membranes and surfactants physicochemical and biological aspects, *Biochimica. et. Biophysica. Acta.*, 1508 (2000), pp. 210–234
66. J. Booth, S. Abbott, S. Shimizu, Mechanism of hydrophobic drug solubilization by small molecule hydrotropes, *J. Phys. Chem. B.*, 116 (2012), pp. 14915–14921
67. S. Kumar, N. Gandhi, Association model of hydrotropy for the effect of hydrotropes on solubility and mass transfer coefficient of acetylsalicylic acid, *Int. J. Pharm. Pharm. Sci.*, 4 (2012), pp. 600–605

68. V. Kumar, C. Jayakumar, C. Raja, N. Gandhi, Hydrotropic aggregation behavior of butyl stearate, *Chem. Mater. Eng.*, 1 (2013), pp. 1–7
69. Y. Cui, Parallel stacking of caffeine with riboflavin in aqueous solutions: the potential mechanism for hydrotropic solubilization of riboflavin, *Int. J. Pharm.*, 397 (2010), pp. 36–43
70. A. Malik, A. Asiri, N. Azum, A Khan, S. Khan, M. Rahman, Kabir-ud-Din, Amphiphilic antidepressant drug amitriptyline hydrochloride under the influence of ionic and non-ionic hydrotropes; micellization and phase separation, *J. Ind. Eng. Chem.*, 19 (2013), pp. 1774–1780
71. Z. Andleeb, A. Malik, Kabir-ud-Din, Effects of pharmaceutical excipients on cloud points of amphiphilic drugs, *J. Colloid. Interf. Sci.*, 361 (2011), pp. 42–48
72. N. Jain, V. Patel, L. Taneja, Hydrotropic solubilization of nifedipine, *Pharmazie*, 43 (1988), pp. 194–196
73. S. Agrawal, S. Pancholi, N. Jain, G. Agrawal, Hydrotropic solubilization of nimesulide for parenteral administration, *Int. J. Pharm.*, 274 (2004), pp. 149–155
74. B. El-Houssieny, E. El-Dein, H. El-Messiry, Enhancement of solubility of dexibuprofen applying mixed hydrotropic solubilization technique, *Drug. Discov. Ther.*, 8 (2014), pp. 178–184
75. K. Girishpai, S. Divya, M. Reddy, L. Kumar, V. Krishna, Solubility enhancement of norfloxacin by hydrotrophy technique, *Int. J. Pharm. Pharm. Sci.*, 6 (2014), pp. 395–397
- 64
76. C. Jayakumar, A. Morais, N. Arunodhaya, N. Gandhi, Solubility enhancement of theophylline drug using different solubilization techniques, *Int. J. Pharm. Clin. Sci.*, 2 (2012), pp. 7–10
77. M. Gupta, V. Joshi, L. Amipara, V. Patel, M. Mahida, Development and evaluation of diclofenac sodium solid dispersion by mixed hydrotropic technique, *Int. J. Pharm. Res. Dev.*, 3 (2011), pp. 90–96
78. J. Madan, K. Pawar, K. Dua, Solubility enhancement studies on lurasidone hydrochloride using mixed hydrotrophy, *Int. J. Pharm. Investig.*, 5 (2015), pp. 114–120
79. M. Margarit, M. Marin, M. Contreras, Solubility of solid dispersions of pizotifen malate and povidone, *Drug. Dev. Ind. Pharm.*, 27 (2001), pp. 517–522
80. Dahima R, Gangwal S., a comparative study of solubility enhancement of enalapril using formulation of solid dispersion and using hydrotropic solubilization technique, *research journal of pharmaceutical biology and chemical science*, oct- dec, 2013, vol. 4, 1301
81. Maheshwari R. K. *et al.*, mixed hydrotrophy: a novel science of solubility enhancement, *Indian J. pharm sci* 2011, mar- april; 73(2): 179-189
82. Omaima ahmed sommour *et al.*, enhancement of solubility and dissolution rate of poorly water- soluble domeridone by the formulation of multi component solid

dispersion using solvent evaporation method, international J. Pharm. Science Rev. res. 20(2), may- june, 2003, 10-19

83. Rasenack N, Hartenhauer H, Müller B. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int. J. Pharm., 2003; 254:137-45.

84. Moyano JR, Blanco MJA, Gines JM, Giordano F. Solid-state characterization and dissolution characteristics of gliclazide-betacyclodextrin inclusion complexes. Int.J. Pharma 1997; 148:211-7.

85. Kalaiselvan R, Mohanta GP, Manna PK, Manavalan R. Studies on Mechanism of Enhanced Dissolution of Albendazole Solid Dispersions with Crystalline Carriers. Indian J Pharm Sci 2006; 68:599-607

86. Nokhodchi A., Javadzadeh Y., Siahi-Shadbad M.R., Barzegar-Jalali M. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J Pharm Pharm Sci 2005; 8:18-25

65

87. Bhise SB, Rajkumar M. Effect of HPMC on Solubility and Dissolution of Carbamazepine Form III in Simulated Gastrointestinal Fluids. Asian Journal of Pharmaceutics 2008; 2(1):38-42.

88. Bakatselou V, Oppenheim RC, Dressman JB. Study in solubilization and wetting effect of bile salts on dissolution of steroid. Pharm Res, 1991; 8:1461-9.

89. Deitzel JM, Kleinmeyer J, Harris D, Beck TNC. 2001. The effect of processing variables on the morphology of electrospun nanofibers and textiles. Polym. 2001, 42, 261-72.

90. Zhang W, Yan E, Huang Z, Wang C, Xin Y, Zhao Q, et al. Preparation and study of PPV/ PVA nanofibers via electrospinning PPV precursor alcohol solution", European polymer 2007;43:892-7.

91. Karanth H, Shenoy VS., Murthy RR. 2006. Industrially feasible alternative approaches in the manufacture in the the solid dispersion: A technical report. AAPS PharmSciTech, 2006;7(4):87.

92. Tsinontides SC, Rajniak P, Hunke W A, Placek J. Freeze drying principles and practice for successful scale-up to manufacturing. Int. J. Pharm 2004; 280(1); 1-16.

93. Vilhelmsen T, Eliassen H, Schaefer T. Effect of a melt agglomeration process on agglomerates containing solid dispersions. Int. J. Pharm, 2005; 303:132-42

94. Reddy sunil beeram *et al.*, united states patent application publication, US 2014/ 0051733 A1, feb 20, 2014

95. [www.drugs.com/pro/uloric.html](http://www.drugs.com/pro/uloric.html)

96. Kulkarni sunisha *et al.*, preformulation- a foundation for formulation development, international journal of pharmaceutical, chemical and biology science, 5 (2), 403- 406

97. Singh S. Stability testing during product development in Jain NK Pharmaceutical product development CBS publisher and distributors. India, (2000) 272-293.

98. Kommanaboyina B., Rhodes CT. Trends in stability testing, with Emphasis on Stability during Distribution and Storage. Drug Dev. Ind. Pharm. 1999; 25:857-867.
99. Carstensen JT. Drug Stability, Principles and Practices, Marcel Dekker, New York (2000)